Metropolitan bank director patent sells $785k in MCB stock

Metropolitan Bank Holding Corp (MCB) reported robust Q2 2025 financial results, surpassing analyst expectations with EPS of $1.76 and revenue of $76.27 million, notably driven by a 15 basis point net interest margin expansion. This strong performance prompted Keefe, Bruyette & Woods to raise its price target to $95 while maintaining an Outperform rating. Concurrently, Director Robert C. Patent executed a sale of 5,999 shares for approximately $785,183, though he retains a significant direct and indirect stake in the company following other recent rebalancing transactions.

Analysis

Metropolitan Bank Holding Corp. (MCB) has demonstrated strong fundamental performance, reporting second-quarter 2025 results that surpassed analyst expectations. The bank posted earnings per share of $1.76 against a forecast of $1.73 and revenue of $76.27 million, significantly outpacing the consensus estimate of $72.55 million. This financial strength was driven by a notable 15 basis point expansion in its net interest margin over the previous quarter and a $0.25 per share pre-provision net revenue beat, signaling enhanced profitability and operational efficiency. The positive results prompted Keefe, Bruyette & Woods to raise its price target to $95 from $81, reaffirming an "Outperform" rating. Contrasting this positive fundamental news is an insider sale by Director Robert C. Patent, who sold 5,999 shares for approximately $785,183 as the stock traded near its 52-week high. However, this sale's significance is tempered by the fact that the director retains a substantial position of 108,685 shares directly and additional holdings indirectly, suggesting the transaction could be for portfolio management or profit-taking rather than a bearish signal on the bank's outlook.

Key Decisions for Investors

• The strong earnings beat, significant net interest margin expansion, and a substantial analyst price target increase to $95 reinforce a bullish thesis for MCB, supporting existing long positions.
• Investors should view the recent insider sale in the context of the stock's appreciation to its 52-week high and the director's large remaining stake, which mitigates the negative signal, though further insider activity should be monitored.
• With the stock trading near its peak, the positive operational performance and analyst upgrade may already be partially priced in, warranting a careful evaluation of the current valuation for new entry points.